Our proprietary cell and gene therapy manufacturing solutions help pioneering companies achieve high-titre, scalable and cost-effective viral vector production, and clinical success.
AAV
Our custom vector design, precision engineering and novel TESSA™ technology help gene therapy pioneers achieve best in class AAV production.
Lentivirus
Our XLenti™ platform provides a scalable lentiviral manufacturing platform using either transient transfection or fully stable producer cell technology.
Adenovirus
Our optimised adenovirus systems and production cell lines advance oncolytic vector and vaccine development.
Get the best results with our comprehensive technical support from our expert scientists.
Talk to us about your projectAre you ready for GMP manufacture?
WuXi Advanced Therapies is a global Contract Testing, Development and Manufacturing Organization (CTDMO) dedicated to accelerating progress and time to market for cell and gene therapies.
INTEGRATED GMP MANUFACTURING AND TESTINGSnapFast™ Plasmids
OXGENE’s SnapFast™ plasmids are versatile and efficient. These modular plasmids are designed to work like 'molecular Lego'. They use a catalogue of well characterised DNA elements that can be easily and reliably inserted into specific locations within the plasmid, so we can rapidly generate large numbers of custom constructs across a range of expression platforms.
We also offer an extensive index of pre-validated licensable plasmids for use in custom expression system development.
Research Grade and GMP-banked HEK293 Suspension Cell Lines
OXGENE's clonal suspension HEK293 cell lines are validated for high-titre production of recombinant AAV (rAAV), lentiviral and adenoviral vectors. These are available for license at both research and GMP grade. All cell lines, including engineered and media adapted derivatives, offer full traceability and grow in defined, animal component free media. Cell lines do not contain the SV40 large T antigen, which ensures regulatory compliance of derived products for in vivo applications.
We're currently developing GMP-compliant, suspension mode, stable lentiviral packaging and producer HEK293 cell lines to offer new, industry leading levels of scalability.
Biomanufacturing News
OXGENE's partners with cell and gene therapy pioneers from clinical candidate holder to CMO to accelerate the journey from laboratory research to clinical manufacture.
Are you thinking about your next discovery programme?
VIEW OUR DISCOVERY SOLUTIONSOur expertise in biology, robotics, in silico analysis and bioinformatics helps cell and gene therapy pioneers advance the discovery phase of their clinical candidates.